Literature DB >> 7532879

Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506.

W Cao1, P Mohacsi, R Shorthouse, R Pratt, R E Morris.   

Abstract

Rapamycin (RPM) is a potent and effective immunosuppressant which we have shown previously to inhibit intimal thickening in rat allograft and balloon-injured arteries. In this report, we have examined the effects of RPM on growth factor-induced vascular smooth muscle cell (VSMC) DNA synthesis. RPM potently inhibited platelet-derived growth factor (PDGF) (IC50 = 5 x 10(-9) M) and basic fibroblast growth factor (bFGF) (IC50 = 8 x 10(-10) M)-induced VSMC DNA synthesis. In contrast, only the highest concentrations of FK506 and CsA significantly altered PDGF- or bFGF-induced VSMC DNA synthesis. Addition of RPM (10(-9) M) at as late as 46 hr after growth factor addition still effectively suppressed bFGF- or PDGF-induced DNA synthesis by 76% and 54%, respectively. The extent of the antagonism of RPM's inhibition of bFGF-induced VSMC DNA synthesis by FK506 was inversely proportional to RPM concentration and directly proportional to FK506 concentration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532879

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  New immunosuppressive drugs and lung transplantation: last or least?

Authors:  J W van den Berg; D S Postma; G H Koëter; W van der Bij
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

Review 3.  Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

Authors:  Pramod Kuchulakanti; Ron Waksman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits.

Authors:  V C Dias; K L Madsen; K E Mulder; M Keelan; R W Yatscoff; A B Thomson
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

Review 5.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats.

Authors:  Paul R Eynott; Michael Salmon; Tung-Jung Huang; Timothy Oates; Paul L Nicklin; K Fan Chung
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

Review 7.  Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.

Authors:  Tom Cornelis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

8.  The use of everolimus in renal-transplant patients.

Authors:  Julio Pascual
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-06-02

Review 9.  A radiologist's guide to novel anticancer therapies in the era of precision medicine.

Authors:  Ali Khader; Rozan Bokhari; Reza Hakimelahi; Christopher Scheirey; Jalil Afnan; Marta Braschi-Amirfarzan; Richard Thomas
Journal:  Eur J Radiol Open       Date:  2022-03-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.